Classification  ||| S:0 E:15 ||| NNP
SAR  ||| S:15 E:19 ||| NNP
modeling  ||| S:19 E:28 ||| NN
of  ||| S:28 E:31 ||| IN
diverse  ||| S:31 E:39 ||| JJ
quinolone  ||| S:39 E:49 ||| JJ
compounds  ||| S:49 E:59 ||| NN
for  ||| S:59 E:63 ||| IN
antimalarial  ||| S:63 E:76 ||| JJ
potency  ||| S:76 E:84 ||| NN
against  ||| S:84 E:92 ||| IN
Plasmodium  ||| S:92 E:103 ||| NNP
falciparum  ||| S:103 E:114 ||| VBD
Both  ||| S:114 E:119 ||| PDT
a  ||| S:119 E:121 ||| DT
development  ||| S:121 E:133 ||| NN
of  ||| S:133 E:136 ||| IN
resistance  ||| S:136 E:147 ||| NN
to  ||| S:147 E:150 ||| TO
artemisinin  ||| S:150 E:162 ||| VB
monotherapy  ||| S:162 E:174 ||| NNS
and  ||| S:174 E:178 ||| CC
lack  ||| S:178 E:183 ||| NN
of  ||| S:183 E:186 ||| IN
effective  ||| S:186 E:196 ||| JJ
vaccine  ||| S:196 E:204 ||| NN
against  ||| S:204 E:212 ||| IN
malaria  ||| S:212 E:220 ||| NNS
have  ||| S:220 E:225 ||| VBP
created  ||| S:225 E:233 ||| VBN
the  ||| S:233 E:237 ||| DT
urgent  ||| S:237 E:244 ||| JJ
need  ||| S:244 E:249 ||| NN
for  ||| S:249 E:253 ||| IN
the  ||| S:253 E:257 ||| DT
development  ||| S:257 E:269 ||| NN
of  ||| S:269 E:272 ||| IN
new  ||| S:272 E:276 ||| JJ
and  ||| S:276 E:280 ||| CC
efficient  ||| S:280 E:290 ||| JJ
antimalarial  ||| S:290 E:303 ||| JJ
agents ||| S:303 E:309 ||| NNS
.  ||| S:309 E:311 ||| .
In  ||| S:311 E:314 ||| IN
this  ||| S:314 E:319 ||| DT
background ||| S:319 E:329 ||| NN
,  ||| S:329 E:331 ||| ,
we  ||| S:331 E:334 ||| PRP
have  ||| S:334 E:339 ||| VBP
developed  ||| S:339 E:349 ||| VBN
here  ||| S:349 E:354 ||| RB
a  ||| S:354 E:356 ||| DT
linear  ||| S:356 E:363 ||| JJ
discriminant  ||| S:363 E:376 ||| JJ
analysis  ||| S:376 E:385 ||| NN
( ||| S:385 E:386 ||| -LRB-
LDA ||| S:386 E:389 ||| NNP
)  ||| S:389 E:391 ||| -RRB-
model  ||| S:391 E:397 ||| NN
and  ||| S:397 E:401 ||| CC
a  ||| S:401 E:403 ||| DT
few  ||| S:403 E:407 ||| JJ
3D-pharmacophore  ||| S:407 E:424 ||| CD
models  ||| S:424 E:431 ||| NNS
for  ||| S:431 E:435 ||| IN
the  ||| S:435 E:439 ||| DT
classification  ||| S:439 E:454 ||| NN
of  ||| S:454 E:457 ||| IN
diverse  ||| S:457 E:465 ||| JJ
quinolone  ||| S:465 E:475 ||| NNS
compounds  ||| S:475 E:485 ||| VBP
based  ||| S:485 E:491 ||| VBN
on  ||| S:491 E:494 ||| IN
their  ||| S:494 E:500 ||| PRP$
antimalarial  ||| S:500 E:513 ||| JJ
potency  ||| S:513 E:521 ||| NN
against  ||| S:521 E:529 ||| IN
Plasmodium  ||| S:529 E:540 ||| NNP
falciparum ||| S:540 E:550 ||| NN
.  ||| S:550 E:552 ||| .
The  ||| S:552 E:556 ||| DT
discriminant  ||| S:556 E:569 ||| JJ
model  ||| S:569 E:575 ||| NN
shows  ||| S:575 E:581 ||| VBZ
70 ||| S:581 E:583 ||| CD
%  ||| S:583 E:585 ||| NN
correct  ||| S:585 E:593 ||| JJ
classification  ||| S:593 E:608 ||| NN
for  ||| S:608 E:612 ||| IN
the  ||| S:612 E:616 ||| DT
test  ||| S:616 E:621 ||| NN
set  ||| S:621 E:625 ||| VBD
compounds  ||| S:625 E:635 ||| VBN
into  ||| S:635 E:640 ||| IN
higher  ||| S:640 E:647 ||| JJR
active  ||| S:647 E:654 ||| JJ
and  ||| S:654 E:658 ||| CC
lower  ||| S:658 E:664 ||| JJR
active  ||| S:664 E:671 ||| JJ
analogues ||| S:671 E:680 ||| NN
.  ||| S:680 E:682 ||| .
The  ||| S:682 E:686 ||| DT
best  ||| S:686 E:691 ||| RBS
pharmacophore  ||| S:691 E:705 ||| JJ
model  ||| S:705 E:711 ||| NN
( ||| S:711 E:712 ||| -LRB-
Hypo-1 ||| S:712 E:718 ||| NNP
)  ||| S:718 E:720 ||| -RRB-
with  ||| S:720 E:725 ||| IN
a  ||| S:725 E:727 ||| DT
correlation  ||| S:727 E:739 ||| JJ
coefficient  ||| S:739 E:751 ||| NN
of  ||| S:751 E:754 ||| IN
0.83  ||| S:754 E:759 ||| NNP
shows  ||| S:759 E:765 ||| VBZ
one  ||| S:765 E:769 ||| CD
hydrogen  ||| S:769 E:778 ||| NN
bond  ||| S:778 E:783 ||| NN
acceptor  ||| S:783 E:792 ||| NNS
( ||| S:792 E:793 ||| -LRB-
HBA ||| S:793 E:796 ||| NNP
)  ||| S:796 E:798 ||| -RRB-
and  ||| S:798 E:802 ||| CC
two  ||| S:802 E:806 ||| CD
ring  ||| S:806 E:811 ||| NN
aromatic  ||| S:811 E:820 ||| NNS
( ||| S:820 E:821 ||| -LRB-
RA ||| S:821 E:823 ||| NNP
)  ||| S:823 E:825 ||| -RRB-
features  ||| S:825 E:834 ||| VBZ
as  ||| S:834 E:837 ||| IN
the  ||| S:837 E:841 ||| DT
essential  ||| S:841 E:851 ||| JJ
structural  ||| S:851 E:862 ||| JJ
requirements  ||| S:862 E:875 ||| NNS
for  ||| S:875 E:879 ||| IN
antimalarial  ||| S:879 E:892 ||| JJ
activity  ||| S:892 E:901 ||| NN
against  ||| S:901 E:909 ||| IN
P  ||| S:909 E:911 ||| NN
falciparum ||| S:911 E:921 ||| NN
.  ||| S:921 E:923 ||| .
Both  ||| S:923 E:928 ||| PDT
the  ||| S:928 E:932 ||| DT
models  ||| S:932 E:939 ||| NNS
may  ||| S:939 E:943 ||| MD
act  ||| S:943 E:947 ||| VB
as  ||| S:947 E:950 ||| RB
in  ||| S:950 E:953 ||| IN
silico  ||| S:953 E:960 ||| JJ
filters  ||| S:960 E:968 ||| NNS
for  ||| S:968 E:972 ||| IN
a  ||| S:972 E:974 ||| DT
virtual  ||| S:974 E:982 ||| JJ
screening  ||| S:982 E:992 ||| NN
and  ||| S:992 E:996 ||| CC
could  ||| S:996 E:1002 ||| MD
be  ||| S:1002 E:1005 ||| VB
utilized  ||| S:1005 E:1014 ||| VBN
for  ||| S:1014 E:1018 ||| IN
the  ||| S:1018 E:1022 ||| DT
selection  ||| S:1022 E:1032 ||| NN
of  ||| S:1032 E:1035 ||| IN
higher  ||| S:1035 E:1042 ||| JJR
active  ||| S:1042 E:1049 ||| JJ
molecules  ||| S:1049 E:1059 ||| NNS
falling  ||| S:1059 E:1067 ||| VBG
within  ||| S:1067 E:1074 ||| IN
the  ||| S:1074 E:1078 ||| DT
applicability  ||| S:1078 E:1092 ||| NN
of  ||| S:1092 E:1095 ||| IN
the  ||| S:1095 E:1099 ||| DT
models ||| S:1099 E:1105 ||| NNS
.  ||| S:1105 E:1107 ||| .
